A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with S. aureus bacteremia
Phase of Trial: Phase I/II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs AP SA01 (Primary)
- Indications Bacteraemia; Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- 14 Aug 2019 According to an Armata Pharmaceuticals media release, study protocol of this trial currently being finalized.
- 09 May 2019 According to an Armata Pharmaceuticals media release, IND application for Staphylococcus aureus bacteremia is planned for 2019.
- 09 May 2019 C3J Therapeutics and AmpliPhi Biosciences have merged together and formed Armata Pharmaceuticals, Inc.